Abstract: This invention provides a suspension for oral administration comprising particles containing amorphous tolvaptan that can inhibit or delay crystallization of amorphous tolvaptan over time in the suspension, and stably maintain high solubility of tolvaptan and excellent absorbability of tolvaptan from the gastrointestinal tract; and a solid formulation for oral administration that can be suspended to prepare the suspension for oral administration at the time of use. This invention relates to a suspension for oral administration, in particular, a syrup, comprising (a) particles containing amorphous tolvaptan, (b) hydroxypropyl methylcellulose (HPMC), and (c) a solvent, wherein the amount of the HPMC (b) is 0.1 to 25% by weight based on the total weight of the suspension for oral administration.

Abstract: An image processing apparatus for executing a plurality of functions related to image processings includes an operation panel and a controller. The operation panel includes a display configured to display a first history screen on which a menu region and a history region are arranged. In the menu region, function buttons corresponding to a plurality of functions are arranged. In the history region, history buttons corresponding to completed image processings are arranged. The controller is configured to control the display to switch from the first history screen to a second history screen on which the history region is expanded, in response to user operation on the operation panel.

Abstract: A method of processing a substrate includes exposing the substrate to a boron-containing precursor to adsorb over the substrate, where the substrate includes a dielectric layer formed over a conductive layer, and the conductive layer is exposed at a bottom of a recess formed in the dielectric layer. The method includes exposing the adsorbed boron-containing precursor to a plasma and filling the recess with a conductive fill material bottom up by a vapor deposition process, where a vertical deposition rate of the conductive fill material is greater than a lateral deposition rate of the conductive fill material.

Abstract: Pharmaceutical formulation comprising centanafadine or a pharmaceutically acceptable salt thereof and an excipient, and related methods of manufacture and use, are disclosed.

Abstract: Pharmaceutical formulation comprising centanafadine or a pharmaceutically acceptable salt thereof and an excipient, and related methods of manufacture and use, are disclosed.

Abstract: An apparatus comprises a plurality of pixels each including a conversion element and a switch, a driving circuit configured to control the switches via drive lines, a bias power supply unit configured to supply a bias potential to the conversion element via a bias line, column signal lines to which signals are output from the plurality of pixels, and a detection unit. The plurality of pixels include a first pixel and a second pixel, which are adjacent to each other in the row direction and are connected to a common column signal line. The switch of the first pixel and the switch of the second pixel are connected to drive lines different from each other. The detection unit determines presence/absence of radiation irradiation based on a current flowing to the bias line.

Abstract: Provided are an outer package material that is for electricity storage devices such as batteries and has such a sufficient anti-electrolytic solution property that the time-dependent reduction of the adhesive strength between a metal foil layer and a sealant layer by an electrolytic solution is suppressed over a long time and a composition for adhesives for giving the outer package material. In an outer package material that is for electricity storage devices and has a structure in which at least a base material layer, a first adhesive layer, a metal foil layer, a second adhesive layer, and a sealant layer are stacked in sequence, a composition containing an isocyanato group and a (meth) acryloyl group and further containing an acid-modified polyolefin (component 1), an active energy ray polymerization initiator (component 3), and a solvent (component 4) is used as a composition for adhesives to form the second adhesive layer.

Abstract: Pharmaceutical formulation comprising centanafadine or a pharmaceutically acceptable salt thereof and an excipient, and related methods of manufacture and use, are disclosed.

Abstract: Pharmaceutical formulation comprising centanafadine or a pharmaceutically acceptable salt thereof and an excipient, and related methods of manufacture and use, are disclosed.

Abstract: A radiographic imaging apparatus according to the present invention includes an orientation measurement unit configured to measure information about an orientation of the radiographic imaging apparatus, wherein the orientation measurement unit performs correction of an output value of the orientation measurement unit based on an operation of radiographic imaging.

Abstract: A radiographic apparatus includes a radiation detector configured to perform radiographic imaging, an orientation measurement unit configured to perform measurement of orientation of the radiation detector, a signal output unit configured to output a trigger signal between reception of a stop signal indicating that a visiting cart carrying the radiation detector is at rest or stops and reception of a completion signal indicating completion of positioning of the radiation detector taken out of the visiting cart and a radiation generation apparatus for the radiographic imaging, the visiting cart being configured to carry the radiation generation apparatus and the radiation detector, and a control unit configured to control the orientation measurement unit to reduce a sampling period of the measurement based on reception of the trigger signal.

Abstract: A setting unit configured to set a reference orientation for calculating the orientation of a radiation detector and a reference orientation for calculating the orientation of the radiation generator sets the reference orientations of the radiation detector and the radiation generator in response to determining that a mobile radiography unit equipped with the radiation generator stands still, with the radiation detector housed, to determine whether the radiation generator and the radiation detector are arranged according to the imaging procedure.

Abstract: This invention provides a suspension for oral administration comprising particles containing amorphous tolvaptan that can inhibit or delay crystallization of amorphous tolvaptan over time in the suspension, and stably maintain high solubility of tolvaptan and excellent absorbability of tolvaptan from the gastrointestinal tract; and a solid formulation for oral administration that can be suspended to prepare the suspension for oral administration at the time of use. This invention relates to a suspension for oral administration, in particular, a syrup, comprising (a) particles containing amorphous tolvaptan, (b) hydroxypropyl methylcellulose (HPMC), and (c) a solvent, wherein the amount of the HPMC (b) is 0.1 to 25% by weight based on the total weight of the suspension for oral administration.

Abstract: Pharmaceutical formulation comprising centanafadine or a pharmaceutically acceptable salt thereof and an excipient, and related methods of manufacture and use, are disclosed.

Abstract: The subject invention provides a novel pharmaceutical solid preparation that has superior disintegration properties and excellent solubility, leading to sufficient absorbability of active ingredients through the gastrointestinal tract. The pharmaceutical solid preparation of the present invention comprises: (a) 7-chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzoazepine and/or salt thereof; (b) hydroxypropylcellulose containing a hydroxypropoxyl group in an amount of 50% or greater; and (c) at least one member selected from the group consisting of carmellose, sodium carboxy methyl starch, crospovidone, and low substituted hydroxypropylcellulose with an average particle diameter of 30 to 70 ?m, and a 90% cumulative particle diameter of 100 to 200 ?m.

Abstract: This invention provides a suspension for oral administration comprising particles containing amorphous tolvaptan that can inhibit or delay crystallization of amorphous tolvaptan over time in the suspension, and stably maintain high solubility of tolvaptan and excellent absorbability of tolvaptan from the gastrointestinal tract; and a solid formulation for oral administration that can be suspended to prepare the suspension for oral administration at the time of use. This invention relates to a suspension for oral administration, in particular, a syrup, comprising (a) particles containing amorphous tolvaptan, (b) hydroxypropyl methylcellulose (HPMC), and (c) a solvent, wherein the amount of the HPMC (b) is 0.1 to 25% by weight based on the total weight of the suspension for oral administration.

Abstract: Pharmaceutical formulation comprising centanafadine or a pharmaceutically acceptable salt thereof and an excipient, and related methods of manufacture and use, are disclosed.

Abstract: A radiation imaging apparatus is provided. The radiation imaging apparatus comprises a plurality of pixels used to acquire a radiation image, and a readout circuit configured to read out a signal from each of the plurality of pixels. Correction image data used for performing offset correction is acquired from the plurality of pixels in an acquisition mode associated with an estimated value of the signal and system noise generated when the readout circuit reads out the signal, the estimated value and the system noise being set according to an imaging mode by a user.

Abstract: Pharmaceutical formulation comprising centanafadine or a pharmaceutically acceptable salt thereof and an excipient, and related methods of manufacture and use, are disclosed.

Abstract: Pharmaceutical formulation comprising centanafadine or a pharmaceutically acceptable salt thereof and an excipient, and related methods of manufacture and use, are disclosed.